CARDIOVASCULAR JOURNAL OF AFRICA • Vol 22, No 1, January/February 2011
AFRICA
43
10. Vedder AC, Linthorst GE, van Breemen MJ,
et al
. The Dutch Fabry
cohort: diversity of clinical manifestations and Gb3 levels.
J Inherit
Metab Dis
2007;
30
: 68–78.
11. Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann
C, Beck M. Natural history of Fabry disease in females in the Fabry
Outcome Survey.
J Med Genet
2006;
43
: 347–352.
12. Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women
are not just carriers, but have a significant burden of disease and
impaired quality of life.
Genet Med
2007;
9
: 34–45.
13. Cox GF. Diagnostic approaches to pediatric cardiomyopathy of metabol-
ic genetic etiologies and their relation to therapy.
Prog Pediatr Cardiol
2007;
24
: 15–25.
14. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clini-
cal manifestations and impact of disease in a cohort of 98 hemizygous
males.
J Med Genet
2001;
38
: 750–760.
15. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease:
clinical manifestations and impact of disease in a cohort of 60 obligate
carrier females.
J Med Genet
2001;
38
: 769–775.
16. Mehta A, Ricci R, Widmer U,
et al
. Fabry disease defined: baseline clini-
cal manifestations of 366 patients in the Fabry Outcome Survey.
Eur J
Clin Invest
2004;
34
: 236–242.
17. Desnick RJ, Brady R, Barranger J,
et al
. Fabry disease, an under-recog-
nized multisystemic disorder: expert recommendations for diagnosis,
management, and enzyme replacement therapy.
Ann Intern Med
2003;
138
: 338–346.
18. Kampmann C, Linhart A, Baehner F,
et al
. Onset and progression of the
Anderson-Fabry disease related cardiomyopathy.
Int J Cardiol
2008;
130
: 367–373.
19. Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A.
Early detection of Fabry cardiomyopathy by tissue Doppler imaging.
Circulation
2003;
107
: 1978–1984.
20. Hughes SE, McKenna WJ. New insights into the pathology of inherited
cardiomyopathy.
Heart
2005;
91
: 257–264.
21. Stöllberger C, Finsterer J. Extracardiac medical and neuromuscular
implications in restrictive cardiomyopathy.
Clin Cardiol
2007;
30
:
375–380.
22. Wood MJ, Picard MH. Utility of echocardiography in the evaluation of
individuals with cardiomyopathy.
Heart
2004;
90
: 707–712.
23. Linhart A, Palecek T, Bultas J,
et al
. New insights in cardiac struc-
tural changes in patients with Fabry’s disease.
Am Heart J
2000;
139
:
1101–1108.
24. Linhart A, Lubanda JC, Palecek T,
et al
. Cardiac manifestations in Fabry
disease.
J Inherit Metab Dis
2001;
24
: 75–83.
25. Elleder M, Bradová V, Smíd F,
et al
. Cardiocyte storage and hypertrophy
as a sole manifestation of Fabry’s disease. Report on a case simulating
hypertrophic non-obstructive cardiomyopathy.
Virchows Arch A Pathol
Anat Histopathol
1990;
417
: 449–455.
26. Ogawa K, Sugamata K, Funamoto N,
et al
. Restricted accumulation of
globotriaosylceramide in the hearts of atypical cases of Fabry’s disease.
Hum Pathol
1990;
21
: 1067–1073.
27. Ishii S, Nakao S, Minamikawa-Tachino R, Desnick RJ, Fan JQ.
Alternative splicing in the alpha-galactosidase A gene: increased exon
inclusion results in the Fabry cardiac phenotype.
Am J Hum Genet
2002;
70
: 994–1002.
28. Sadick N, Thomas L. Cardiovascular manifestations in Fabry disease:
a clinical and echocardiographic study.
Heart Lung Circ
2007;
16
:
200–206.
29. Shah JS, Lee P, Hughes D,
et al
. The natural history of left ventricular
systolic function in Anderson-Fabry disease.
Heart
2005;
91
: 533–534.
30. Kampmann C, Baehner F, Whybra C,
et al
. Cardiac manifestations of
Anderson-Fabry disease in heterozygous females.
J Am Coll Cardiol
2002;
40
: 1668–1674.
31. Linhart A, Kampmann C, Zamorano JL,
et al
. Cardiac manifestations of
Anderson-Fabry disease: results from the international Fabry outcome
survey.
Eur Heart J
2007;
28
: 1228–1235.
32. Pinderski LJ, Strotmann J. Congestive heart failure in Fabry cardio-
myopathy: Natural history experience in an international cohort of 1,448
patients.
J Heart Lung Transplant
2006;
25
: S70.
33. Weidemann F, Breunig F, Beer M,
et al
. The variation of morpho-
logical and functional cardiac manifestation in Fabry disease: potential
implications for the time course of the disease.
Eur Heart J
2005;
26
:
1221–1227.
34. Utsumi K, Ueda K, Watanabe M,
et al
. Thrombosis in Japanese patients
with Fabry disease.
J Neurol Sci
2009. Available at:
-
journal.com/article/S0022-510X(09)00413-4/abstract. Last accessed on
April 15, 2009.
35. Kovarnik T, Mintz GS, Karetova D,
et al
. Intravascular ultrasound
assessment of coronary artery involvement in Fabry disease.
J Inherit
Metab Dis
2008;
31
: 753–760.
36. Kalliokoski RJ, Kalliokoski KK, Sundell J,
et al
. Impaired myocar-
dial perfusion reserve but preserved peripheral endothelial function in
patients with Fabry disease.
J Inherit Metab Dis
2005;
28
: 563–573.
37. Cortigiani L, Rigo F, Gherardi S, Galderisi M, Sicari R, Picano
E. Prognostic implications of coronary flow reserve on left ante-
rior descending coronary artery in hypertrophic cardiomyopathy.
Am J
Cardiol
2008;
102
: 1718–1723.
38. Roudebush CP, Foerster JM, Bing OH. The abbreviated PR interval of
Fabry’s disease.
N Engl J Med
1973;
289
: 357–358.
39. Shah JS, Hughes DA, Sachdev B,
et al
. Prevalence and clinical signifi-
cance of cardiac arrhythmia in Anderson-Fabry disease.
Am J Cardiol
2005;
96
: 842–846.
40. Weidemann F, Strotmann JM, NiemannM,
et al
. HeartValve Involvement
in Fabry Cardiomyopathy.
Ultrasound Med Biol
2008. Available at:
Last accessed on April 14, 2009.
41. Hoigné P, Attenhofer Jost CH, Duru F,
et al
. Simple criteria for differen-
tiation of Fabry disease from amyloid heart disease and other causes of
left ventricular hypertrophy.
Int J Cardiol
2006;
111
: 413–422.
42. Toro R, Perez-Isla L, Doxastaquis G,
et al
. Clinical usefulness of tissue
Doppler imaging in predicting preclinical Fabry cardiomyopathy.
Int J
Cardiol
2009;
132
: 38–44.
43. Pieroni M, Chimenti C, De Cobelli F,
et al.
Fabry’s disease cardiomyopa-
thy: echocardiographic detection of endomyocardial glycosphingolipid
compartmentalization.
J Am Coll Cardiol
2006;
47
: 1663–1671.
44. Kounas S, Demetrescu C, Pantazis AA,
et al
. The binary endocar-
dial appearance is a poor discriminator of Anderson-Fabry disease from
familial hypertrophic cardiomyopathy.
J Am Coll Cardiol
2008;
51
:
2058–2061.
45. Koskenvuo JW, Engblom E, Kantola IM,
et al
. Echocardiography in
Fabry disease: diagnostic value of endocardial border binary appearance.
Clin Physiol Funct Imaging
2009;
29
: 177–180.
46. Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A.
Early detection of Fabry cardiomyopathy by tissue Doppler imaging.
Circulation
2003;
107
: 1978–1984.
47. Germans T, van Rossum AC. The use of cardiac magnetic resonance
imaging to determine the aetiology of left ventricular disease and cardio-
myopathy.
Heart
2008;
94
: 510–518.
48. Moon JC, Sachdev B, Elkington AG,
et al
. Gadolinium enhanced cardio-
vascular magnetic resonance in Anderson-Fabry disease. Evidence for a
disease specific abnormality of the myocardial interstitium.
Eur Heart
J
2003;
24
: 2151–2155.
49. Moon JC, Reed E, Sheppard MN,
et al
. The histologic basis of late gado-
linium enhancement cardiovascular magnetic resonance in hypertrophic
cardiomyopathy.
J Am Coll Cardiol
2004;
43
: 2260–2264.
50. Rudolph A, Abdel-Aty H, Bohl S,
et al
. Noninvasive detection of fibro-
sis applying contrast-enhanced cardiac magnetic resonance in different
forms of left ventricular hypertrophy relation to remodeling.
J Am Coll
Cardiol
2009;
53
: 284–291.
51. Silva C, Moon JC, Elkington AG, John AS, Mohiaddin RH, Pennell DJ.
Myocardial late gadolinium enhancement in specific cardiomyopathies
by cardiovascular magnetic resonance: a preliminary experience.
J
Cardiovasc Med
(Hagerstown) 2007;
8
: 1076–1079.
52. Bohl S, Wassmuth R, Abdel-Aty H,
et al
. Delayed enhancement cardiac
magnetic resonance imaging reveals typical patterns of myocardial
injury in patients with various forms of non-ischemic heart disease.
Int
J Cardiovasc Imaging
2008;
24
: 597–607.
53. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed
enhancement cardiovascular magnetic resonance assessment of non-
